The study is comprised of 2 parts. Part 1 (Phase 1) involves varsetatug masetecan dose finding to identify the recommended Phase 2 dose (RP2D) of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin in the second line treatment setting. Part 2 (Phase 2) will further assess safety, tolerability and antitumor activity doses and schedules of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin in this second line patient population, based on the dose finding results from Part 1 of this trial. In addition, Part 2 will also further evaluate dose and schedules of varsetatug masetecan in combination with bevacizumab (without 5-FU and leucovorin) in the second line treatment setting based on the dose finding results in the ongoing Phase 1 Study CTMX-2051-101 assessing the varsetatug masetecan combination with bevacizumab (NCT06265688).
